Protagenic Therapeutics’ Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
As published in Behavioural Pharmacology, two days of PT00114 treatment reduced corticosterone levels and attenuated anxiety-like behavior in chronically stressed...
Hemostemix to Highlight Commercial Phase I Longevity Treatment at Small Cap Growth Investor Conference